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ABSTRACT
Objectives To quantify the extent to which guideline
recommendations for routine testing for HIV are adhered
to outside of genitourinary medicine (GUM), sexual
health (SH) and antenatal clinics.
Methods A systematic review of published data on
testing levels following publication of 2008 guidelines
was undertaken. Medline, Embase and conference
abstracts were searched according to a predeﬁned
protocol. We included studies reporting the number of
HIV tests administered in those eligible for guideline
recommended testing. We excluded reports of testing in
settings with established testing surveillance (GUM/SH
and antenatal clinics). A random effects meta-analysis
was carried out to summarise level of HIV testing across
the studies identiﬁed.
Results Thirty studies were identiﬁed, most of which
were retrospective studies or audits of testing practice.
Results were heterogeneous. The overall pooled estimate
of HIV test coverage was 27.2% (95% CI 22.4% to
32%). Test coverage was marginally higher in patients
tested in settings where routine testing is recommended
(29.5%) than in those with clinical indicator diseases
(22.4%). Provider test offer was found to be lower
(40.4%) than patient acceptance of testing (71.5%).
Conclusions Adherence to 2008 national guidelines
for HIV testing in the UK is poor outside of GUM/SH and
antenatal clinics. Low levels of provider test offer appear
to be a major contributor to this. Failure to adhere to
testing guidelines is likely to be contributing to late
diagnosis with implications for poorer clinical outcomes
and continued onwards transmission of HIV. Improved
surveillance of HIV testing outside of specialist settings
may be useful in increasing adherence testing guidelines.
INTRODUCTION
In 2011, there were an estimated 96 000 people
living with HIV in the UK with almost one in four
thought to be unaware of their infection.1 In the
same year, 6280 individuals were newly diagnosed
and 47% of these cases were at a late stage of infec-
tion (CD4 cell count <350 cells/mm3).1 Patients
diagnosed late experience a higher risk of develop-
ing AIDS and a tenfold increased risk of death
within a year of diagnosis.2–4 Timely identiﬁcation
of those who are HIV-positive and appropriate
referral into care services is essential not only for
the reduction of HIV-associated morbidity and
mortality but also for the prevention of onwards
transmission of the virus. Reducing late HIV
diagnosis is a key indicator of the Public Health
Outcomes Framework set by the Department of
Health (DoH),5 and the primary means of achiev-
ing this is widespread testing in populations and
settings at increased risk of HIV infection.
The latest national guidelines on HIV testing
were published in October 2008. The guidelines
were published by the British HIV Association
(BHIVA) and written in collaboration with the
British Infection Society (BIS) and the British
Association for Sexual Health and HIV (BASHH).
These guidelines were intended to promote an
increase in HIV testing in all healthcare settings to
reduce the proportion of individuals with undiag-
nosed HIV infection. The authors of the guidelines
state the reason for the need of their publication as
being (a) misconceptions regarding HIV testing
remaining a hindrance to increased testing; (b) the
importance of both the individual patient and
public health beneﬁts of increased testing and (c)
the need for up-to-date guidance that would enable
any clinician to perform an HIV test within good
clinical practice, thereby encouraging the ‘normal-
isation’ of HIV testing.6 These guidelines recom-
mended HIV testing in a wider range of clinical
settings and populations including those with indi-
cator diseases, all medical admissions and new
registrants in primary care in areas with a diag-
nosed adult HIV prevalence of greater than 2 per
1000 population (please see online appendix a,
supplementary data). The guidelines have addition-
ally been endorsed by the National Institute of
Health and Care Excellence and incorporated into
their pathway for strategy, policy and commission-
ing on HIV testing and prevention.7 8
There have been improvements in earlier diagno-
sis for HIV in the UK. According to Public Health
England ﬁgures, there has been a gradual decrease
in the proportion of people diagnosed late with
HIV in the UK, from 60% in 2002 to 47% in
20111; however, this remains high, suggesting that
testing programmes continue to miss people at an
early stage in their infection. HIV testing is rou-
tinely monitored in genitourinary medicine
(GUM), sexual health (SH) and antenatal clinics
(ANC) where uptake is high, with 70% of GUM
and 97% of ANC attendees being tested for HIV
in 2010; these locations account for 47% and 31%
of total HIV tests in the UK, respectively. However,
there is no routine monitoring of testing in other
(non-specialist) clinical settings or populations, and
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therefore adherence to national guidelines is unknown. To
inform decision making about future HIV-testing initiatives, we
reviewed evidence of adherence to national guidelines in settings
not covered by existing surveillance.
METHODS
Search strategy and inclusion/exclusion criteria
We carried out a systematic review and meta-analysis on levels
of adherence to national guideline recommended HIV testing in
non-specialist settings. A predeﬁned protocol (available as
online supplementary ﬁle ‘Review Protocol’) detailing inclusion
and exclusion criteria was developed; two authors (RE and
SMG) independently used a set combination of terms (HIV,
human immunodeﬁciency virus test*, screen*, diagnos*, United
Kingdom, UK, England, Northern Ireland, Scotland, Wales,
Britain, British, English, Scottish, Welsh, Northern Irish) to
search MEDLINE, Embase, Maternity and Infant Care and
PsychINFO databases via the search engine Ovid. The ﬁnal
search was run on 28 February 2013. In addition, bibliographies
from eligible papers, conference abstracts and grey literature
(including relevant reports7 8) were hand searched. Studies were
included if they measured HIV test coverage in a deﬁned, eli-
gible population. Studies were excluded if they related to testing
in GUM/SH or ANC (specialist) clinics, included data from
before September 2008 or were conducted outside the UK.
Studies not measuring HIV testing levels as an outcome were
also excluded as were those measuring HIV testing in commu-
nity settings as, although testing in these settings is encouraged,
it is not explicitly recommended in UK national guidelines. In
order to identify as wide a range of studies measuring HIV
testing levels as possible, all quantitative study designs and meth-
odologies were included. Where key information for article
inclusion was missing, an online search for conference presenta-
tions/posters was performed and authors were contacted for
additional data. Articles were only excluded after the deadline
period for author reply had passed.
Data extraction
Data extraction was undertaken separately by two authors, and
information on the following variables was retrieved: author(s),
exposure status or risk group (if applicable), primary HIV
testing outcome (how receipt of HIV test was conﬁrmed),
exclusion criteria, time period and duration of data collection,
population, setting (and Public Health England estimations for
diagnosed HIV prevalence per 1000 population 15–59 year
olds), type and number of centres, study design and methods,
measure or reporting method, type of test used, method of
service delivery, opt-in/opt-out model, number of patients eli-
gible for testing, number offered testing, number tested and
number with positive test result.
Data analysis
Studies were classiﬁed into two groups according to patient
population or setting where testing took place: persons diag-
nosed with a disease indicative of HIV infection and persons
attending a setting where routine HIV screening should be
undertaken (excluding GUM/SH and ANC settings) (see online
appendix a, supplementary data).5 Test coverage, deﬁned as the
percentage of those eligible for HIV testing who were offered
and accepted an HIV test, was calculated for each study identi-
ﬁed. Additional outcomes including (a) test offer level deﬁned
as the percentage of those eligible for testing who were offered
a test), (b) test acceptance level (deﬁned as the percentage of
those offered an HIV test who were tested) and (c) seropreva-
lence level (deﬁned as the percentage of those testing positive
for HIV) were calculated where this information was available.
Using a random effects model, stratiﬁed analyses were per-
formed by group. Clopper–Pearson 95% CIs were calculated for
each study input. CIs for these results were capped at 0% and
100% for presentation of pooled estimates as percentages.8
Cochran’s test of heterogeneity (Q statistic) and I2 statistic was
used to assess the presence of and quantify the extent of
between-study heterogeneity in testing prevalence estimates.9
Univariate meta-regression was used to investigate heterogen-
eity in overall testing coverage. There were too few studies to
explore this for the other outcomes. Proportions were trans-
formed to logits using a continuity correction of 0.1% where
the number of patients tested for HIV was either equal to zero
or the number of eligible patients.10 If a covariate was signiﬁ-
cantly associated with the prevalence estimates, the percentage
of between-study variability explained by the covariate (R2) was
calculated as 100*(1− (τ2 regression model with covariate/ τ2
regression without covariate)). Analyses were completed in
STATA v.11.0 (StataCorp, College station, Texas, USA).
Figure 1 Flowchart of search results
and selection of papers.
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RESULTS
The search identiﬁed 1226 references that were screened;
after exclusion of duplicates and undertaking a title and
abstract screen, 163 full-text articles were evaluated for full
inclusion. Of these, 30 reports that measured levels of HIV
testing in a range of recommended settings were identiﬁed
(ﬁgure 1). Fourteen were cross-sectional studies or retrospect-
ive studies (audits) from hospital settings using either case
note review or extraction of data from electronic or paper
records. Data from 12 were in journal publications, and data
from the remaining 18 studies were extracted from published
reports or conference abstracts. Ten studies were in patients
diagnosed with an indicator disease and 20 in people attending
services where routine HIV testing was recommended due to
diagnosed prevalence in the local population. Information for
all 30 studies identiﬁed can be found in online supplementary
data ﬁle appendix b: characteristics of studies included:
methods, measures and testing levels and appendix c: supple-
mentary data tables for studies identiﬁed by group.
Table 1 shows the pooled estimates for the percentage of eligible
patients who received HIV tests in the two groups, the percentage
who were offered and accepted testing, and HIV prevalence from
those studies that reported these outcomes. There was considerable
heterogeneity within and between the patient groups, with an
overall pooled estimate of 27.2% (95% CI 22.4% to 32.0%) of
those eligible being tested. This level of heterogeneity is illustrated
in the forest plots (ﬁgure 2A,B) for both groups. The higher
pooled estimate of the two was 29.5% (95% CI 23.6% to
35.4%), with individual results ranging from 0.5% (95% CI 0.4%
to 0.7%) in Page et al11 to 83.2% (95% CI 74.4% to 89.9%) in
Chan et al12 (ﬁgure 2B). Testing was less likely in patients with dis-
eases indicative of HIV infection, with a pooled estimate of 22.4%
(95% CI 13.9% to 30.9%) and result ranging from 5.9% (95%
CI 4.1% to 8.2%) in Gupta and Lechelt to 65.4% (95% CI
60.1% to 70.5%) in Thorburn et al13 There was considerable
between-study heterogeneity across studies as illustrated by the I2
statistic value, which was consistently over 97%.
A meta-regression was undertaken to explore other study char-
acteristics that may contribute to the heterogeneity, and the
results are presented in table 2. Covariates assessed as contribu-
tors to heterogeneity include location of testing (London or
non-London), type of test administered (laboratory serological or
point-of-care testing), testing strategy (opt-in or opt-out), service
model (standard practice, staff training or GUM specialist testing)
and study type (retrospective or prospective). None of these
factors appeared to contribute signiﬁcantly to the level of hetero-
geneity, and the results here should be interpreted with caution as
many of the variables had small sample sizes, for example, there
were only three studies in the ‘GUM specialist testing’ group of
the service model. In a separate meta-regression model looking at
contribution of study type in test coverage level exclusively in
persons attending screening settings (the only group to have both
retrospective and prospective study types), study type was found
to be a signiﬁcant contributor to the level of heterogeneity seen
in test coverage in these studies (OR 6.3, 95% CI 1 to 38.4). The
adjusted R2 for this meta-regression indicates that 15.1% of
between-study variance in the pooled estimate for this testing
across studies could be explained by study type in this group. The
result here should again be carefully interpreted as only four
studies were included in the ‘Retrospective’ group of this model.
Fourteen studies reported both the number of tests being
offered to those eligible and the number of those offered tests
who were tested. The pooled estimate for HIV test offer level isT
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at 40.4% (95% CI 24.3% to 56.7%) and the pooled estimate
for HIV uptake levels is 71.5% (95% CI 56.0% to 86.9%).
These results are presented in table 1 and show that the pooled
estimate of eligible people offered an HIV test was 9.3% (95%
CI 1.2% to 17.3%) in patients diagnosed with an indicator
disease, which was lower than that seen in persons attending
screening settings at 29.5% (95% CI 23.6% to 35.4%). Uptake,
that is, the percentage of those offered testing who accepted
was 69.2% (95% CI 52.8% to 85.6%) in persons attending
screening settings and 87.4% (95% CI 57.7% to 100.0%) in
Figure 2 (A, B) Forest plots of
percentage of eligible patients tested
by group (A). Patients with an
indicator disease (B). Patients
attending a clinical setting where
routine HIV testing is recommended
(excluding genitourinary medicine/
sexual health and antenatal clinics).
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patients diagnosed with indicator diseases, indicating that test
offer is lower for patients with indicator diseases despite a
higher test acceptance level in this group.
Of the 30 studies, 23 reported the number of those patients
who tested positive for HIV, and the meta-analysis results for
the seroprevalence observed in these studies are also presented
in table 1. The pooled seroprevalence was 0.5% (95% CI 0.3%
to 0.7%), with a higher seroprevalence seen in patients diag-
nosed with an indicator disease (2.7%, 95% CI 1.1% to 4.4%)
than those tested in screening settings (0.4%, 95% CI 0.2% to
0.6%).
DISCUSSION
In this review, we found that the estimated percentage of
patients eligible for HIV testing who receive a test is 27.2%
(95% CI 22.4% to 32%). This low level of testing suggests
that adherence to the 2008 UK guidelines for HIV testing is
poor in recommended populations and settings. Analysis of
test offer and acceptance levels suggests that the low overall
level of testing is likely to be due to low levels of provider
test offer and not patient acceptance. Provider test offer to
those eligible was estimated to be only 40.4% (95% CI
24.3% to 56.7%) while patient acceptance of testing was
71.5% (95% CI 56% to 86.9%). This trend of low provider
test offer and high-patient test acceptance has previously
been seen in other countries in Europe and in the USA,14 15
where it has been suggested that it indicates that health pro-
viders assess risk differently, are more likely to offer testing
to patients they perceive to be at high risk or more likely to
accept testing. Aside from this, operational and training bar-
riers such as inadequate training for routine test offer, lack
of time or difﬁcultly in ordering an HIV test have also been
cited as reasons contributing to low levels of health provider
test offer.16–18
The highest level of testing (83.2%) was reported by Chan
et al, who assessed the uptake and acceptability during a study
of consecutive HIV test offer in medical admissions in Croydon.
A previous audit of HIV testing in this hospital had showed a
very low coverage of less than 1% prior to the prospective
study. This indicates that consecutive test offer as undertaken in
the prospective study can yield a much higher level of coverage.
Cleary implementing a study of HIV offer is an intervention,
and this may explain the signiﬁcant difference in coverage in
screening settings between retrospective audits and prospective
studies. However, some retrospective studies also report
high levels of testing, such as in Rosenvinge et al19 with 80.7%,
indicating that good coverage can be achieved in the absence of
a prospective study.
A higher HIV seroprevalence was found in patients tested
who presented with a disease indicative of HIV infection at
2.7% (95% CI 1.1% to 4.4%) than found in those tested in set-
tings where routine HIV testing should be undertaken 0.4%
(95% CI 0.2% to 0.6%), and the overall pooled seroprevalence
from studies was found to be 0.5% (95% CI 0.3% to 0.7%).
These seroprevalence estimates exceed the threshold level 0.1%
seropositivity of total tests administered deemed as cost-effective
by CDC,20 indicating that HIV testing in these settings and
populations is cost-effective and is likely to continue to be so
with increased test coverage.
Of those presenting with indicator disease conditions (includ-
ing tuberculosis, glandular fever and other blood borne viruses),
an estimated 22.4% (95% CI 13.9% to 30.9%) received an HIV
test compared with an estimated 29.5% (95% CI 23.6% to
35.4%) of those attending screening settings where routine HIV
testing should be undertaken. Although the odds of being tested
for HIV if diagnosed with an indicator disease condition do not
appear to signiﬁcantly contribute to the difference seen in test
coverage (0.8, p=0.67), this group represents a particularly
high-risk population who are easily identiﬁed. Testing in this
group is a long-standing recommendation of guidelines prior to
2008, so these results are very disappointing. HIV testing in
patients with indicator diseases has previously been explored.
Read et al21 found that 37% of patients newly diagnosed with
HIV in their secondary care hospital had presented to health-
care services with an HIV indicator condition in the preceding
12 months but had not been tested at the time. In a recent pro-
spective study looking at the effectiveness of indicator
condition-guided testing for HIV, Sullivan et al22 found an HIV
prevalence of 1.8% (95% CI 1.42% to 2.34%) across European
centres, similar to our estimate of 2.7% (95% CI 1.1% to
4.4%). Furthermore, ﬁndings from an analysis from 13 counsel-
ling and testing sites in Italy indicated that those presenting late
with HIV were probably already infected at the time their initial
indictor disease was diagnosed, but that there was a median
lapse of 22.6 months between indicator disease diagnosis and
HIV diagnosis.23 The lack of adherence to guidelines in this
group therefore is likely to be hindering timely identiﬁcation of
HIV greatly.
There are a number of limitations to this study, primarily the
lack of a comparable routine data set with relevant information.
Due to this we have been reliant on a relatively small number of
reports from local audits and studies that included a wide
variety of populations, settings, duration and methods used for
measuring HIV testing. However, as guideline recommendations
are broad in their description of settings and populations,
further restriction in inclusion criteria was not possible. The
Table 2 Predictors of HIV testing rates among eligible patients:
meta-regression of results from studies identified
Covariate N studies OR (95% CI) p Value
Patient group
Patients presenting with
indicator disease conditions
10 0.8 (0.2 to 2.6) 0.67
Persons attending screening
settings
20 1 (ref)
Location of study
London 14 1 (ref)
Non-London 16 0.5 (0.2 to 1.6) 0.26
Type of HIV test
Laboratory 7 1 (ref)
Point-of-care 6 0.8 (0.2 to 4) 0.75
Service model*
Usual practice 18 1 (ref)
Added staff training 9 1.3 (0.4 to 4.8) 0.62
GUM specialist testing 3 3.5 (0.5 to 24) 0.2
Testing strategy
Opt-out 12 1 (ref)
Opt-in 9 1 (0.3 to 3.2) 0.99
Study type
Retrospective 14 1 (ref)
Prospective 16 2.6 (0.9 to 7.7) 0.08
*With only three studies in one of the categories, this result should be interpreted
with caution due to lack of power.
GUM, genitourinary medicine.
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studies were of varied quality, and this could not be systematic-
ally assessed as many were published as reports or conference
abstracts rather than peer-reviewed papers. Data quality was also
variable, with some dependent on patient self-report of previous
tests to deﬁne eligibility. Several studies were interventional in
nature, offering consecutive HIV tests in recommended settings
and this may have contributed to an overestimate of testing in
routine conditions. However, these limitations could only be
overcome through the implementation of standards for report-
ing in the context of some surveillance system such as those that
already exist in established testing settings.
There was a great deal of heterogeneity in the data with some
I2 statistic values at 100%, and as a result caution should be
taken in interpreting the summary statistics presented for illus-
tration as an average proportion. True study percentages are
likely to vary greatly around the estimate points presented. We
do not claim to present a true level of overall test coverage level
but rather an estimate from the data collected and we have tried
to understand some of the variation that was associated with
this. Meta-regression did not identify any factor as the majority
a contributor to the between-study variance seen, and it is likely
that much more of the heterogeneity could be explained by
factors that could not be measured in the meta-regression either
due to insufﬁcient study numbers or the fact that potential
explanatory variables were not reported for all studies.
CONCLUSION
The results of this review and meta-analysis indicate adherence
to 2008 national guidelines for HIV testing in the UK is poor
and that low levels of provider test offer appear to be a major
contributor to this, particularly in patients presenting with an
indicator disease. Failure to adhere to testing guidelines is
likely to be contributing to late diagnosis with implications for
poorer clinical outcomes and continued onwards transmission
of HIV. Improved surveillance of HIV testing outside of spe-
cialist settings may be useful in increasing adherence testing
guidelines.
Key messages
▸ Findings indicate HIV test coverage in the UK is poor and
low levels of provider test offer appear to be the main
contributor to this.
▸ Seroprevalence estimates show that HIV testing is
cost-effective and increasing HIV testing in line with national
guidelines would also be cost-effective.
▸ Further exploration of effective methods for the routine offer
of HIV testing in recommended settings.
▸ Better methods for the clear dissemination of routine HIV
testing messages to non-specialist clinicians are required.
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